Clinical trials: Psychiatric Illness
Schizophrenia
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00101634
- Testing
- Paliperidone palmitate
- Volunteers
- 518 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Patient Tolerability Study of GSK163090
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
- Trial name
- NCT00559299
- Testing
- GSK163090
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada
Schizophrenia, Antipsychotics
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
Interventional, multicenter, open-label, 20 weeks study To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.
- Conditions
- Schizophrenia, Antipsychotics, Long-Acting Injection, LAI
- Trial name
- MAESTRO (NCT03376763)
- Testing
- Abilify maintena
- Where
- 27 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).
- Trial name
- NCT05666687
- Testing
- MIJ821
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia
- Trial name
- NCT00036088
- Testing
- Olanzapine
- Where
- 60 sites in United States, Argentina and 10 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients
The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.
- Trial name
- NCT06079827
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- MaxWell Clinic, PLC
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
Depressive Disorder, Major
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD- 2 (NCT07775300)
- Testing
- Brenipatide
- Where
- 170 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Autism Spectrum Disorder
Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1
This is a project to be funded by a Fast-Track Small Business Innovative Research to build and test the feasibility of a new software prototype called V-Motive which will facilitate the combination of two proven autism behavioral…
- Trial name
- NCT02500771
- Testing
- ABA therapy enhanced with V-Motive software
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Experiad LLC
Epilepsy
WEUSKOP6166: Lamotrigine and Aseptic Meningitis
The objective of the study is to quantify the number of cases of aseptic meningitis among users of Lamotrigine. This study is a cross-sectional study design using data on lamotrigine patients within the Thomson Reuters…
- Trial name
- NCT01657864
- Testing
- Lamotrigine
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
A Study in Patients With Erectile Dysfunction
The purpose of this study is to investigate if treatment in erectile dysfunction with a long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer treatment adherence and better long term outcomes (over…
- Trial name
- NCT01122264
- Testing
- Tadalafil, Sildenafil Citrate
- Where
- 45 sites in France, Germany and 6 more
- Volunteers
- 770 people
- Sponsor
- Eli Lilly and Company
Rett Syndrome
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
- Trial name
- ASPIRE (NCT07480564)
- Testing
- TSHA-102
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Taysha Gene Therapies, Inc.
Major Depressive Disorder
A Study of Intermittent Doses of CERC-301 in MDD
There is a significant unmet medical need for rapidly acting treatment of subjects with severe major depressive disorder (MDD) who have not adequately responded to antidepressant therapy.
- Trial name
- NCT02459236
- Testing
- CERC-301
- Where
- 13 sites in United States
- Volunteers
- 115 people
- Sponsor
- Avalo Therapeutics, Inc.
ADHD
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with…
- Trial name
- NCT06359899
- Testing
- AK0901 capsule
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Major Depressive Disorder
Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects
This study will investigate the tolerability and pharmacokinetics of Hypidone Hydrochloride by multiple doses in 36 healthy male and female subjects who are of 18 to 55 years old.
- Trial name
- NCT04598607
- Testing
- Hypidone Hydrochloride tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Post Traumatic Stress Disorder
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD
Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of PTSD The aim of this study: To better…
- Trial name
- NCT05242367
- Testing
- Modius Spero active device
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- Neurovalens Ltd.
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.